Okayama University Medical Research Updates (OU-MRU)

2021.02 Vol.88

Source: Okayama University (JAPAN), Public Relations Division

For immediate release: 22 February 2021

Okayama University research: Nanotechnology for making cancer drugs more accessible to

the brain

(Okayama, 22 February) In a study reported in the *Journal of Controlled Release*, researchers from Okayama University describe the use of nanocarriers in selectively transporting anticancer drugs to brain tumors.

Glioblastoma is an aggressive form of brain cancer that is best treated with boron neutron capture therapy (BNCT). BNCT involves the use of an agent that delivers boron into tumor tissues. When subsequently hit with radiation, boron (typically the 10B isotope is used) emits particles that kill neighboring cells. However, current methods do not cargo boron into cancer cells homogenously. Now, Associate professor MICHIUE Hiroyuki and Okayama university Neutron Therapy Research Center (NTRC) team have successfully used a nanocarrier that selectively delivers boron into brain tumors.

The carrier, known as the A6K peptide, is a nano-scale structure that spontaneously clusters to form hollow tubes when immersed in water. The peptide has a positively charged core, which attracts any negatively charged molecules in the vicinity and traps them inside it. Another bonus feature is that the assembled tubes easily pass through cell membranes. The researchers first combined varying concentrations of the A6K peptide and BSH (disodium undecahydro-mercapto-closo-dodecacarborate), a negatively charged boron-containing chemical. The ensuing complexes formed were observed under the electron microscope.

At high ratios of A6K: BSH a chaotic mess of branched complexes were produced, whereas at concentrations of 1:5 and lower, ordered spherical complexes were created. Seemingly, the BSH particles had been engulfed. These low concentration complexes were then introduced into glioma cells to find that they effectively penetrated the cancerous cells. However, the localization of only BSH into glioma cells was almost ten times less. A6K was thus highly competent in ushering BSH particles into the cells. Additionally, A6K-BSH did not induce any toxicity in the cells by itself.


To then investigate how the complexes were transported in the body, A6K-BSH was injected into the tails of mice with glioblastoma. Within 2 hours the levels of A6K-BSH peaked within the brain tumors of these mice. What's more, no drug complex was found in healthy tissues. Finally, the tumor-killing properties of A6K-BSH were assessed by treating cells with the complex and then bombarding the cells with radiation for 30 minutes. Within 24 hours, cells irradiated for 15 minutes or more stopped proliferating. The BSH-containing nanotubes were successful in targeting and preventing the growth of cancer cells.

"We aimed to demonstrate a new boron delivery system based on A6K peptide and BSH, and open up a novel direction for boron agents in the next generation of BNCT," claim the researchers. They also point out the convenience of using this system which simply involves one mixing step before use. While the system remains to be fully tested in animals, it paves the way for directed killing of hard-to-reach tumors.

Background

Boron neutron capture therapy (BNCT): BNCT is a commonly used combination of drug and radiation therapy for cancers that are hard to target with traditional chemotherapy. BNCT involves transferring boron-containing compounds into cancer cells, and subsequently irradiating the cells with neutron beams. However, there are several challenges associated with traditional BNCT, such as ensuring that boron is escorted into tissues uniformly.

Pharmaceutical scientists are now designing novel delivery systems for these boroncontaining compounds. A vast array of synthetic polymers has been investigated for this purpose, but these pose additional issues such as toxicity and degradation of the boron agents. The A6K nanotube is a small peptide molecule that has been used to deliver gene therapy in the past. This study demonstrates that the peptide can usher many more substances.



Caption

Colonies of cells treated with the A6K-BSH complex reduced greatly when exposed to radiation for 15 minutes or more suggesting that the growth of cancer cells was halted.

Reference

Hiroyuki Michiue, Mizuki Kitamatsu, Asami Fukunaga, Nobushige Tsuboi, Atsushi Fujimura, Hiroaki Matsushita, Kazuyo Igawa, Tomonari Kasai, Natsuko Kondo, Hideki Matsui, Shuichi Furuya. Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture therapy (BNCT). Journal of Controlled Release, 2020 Nov 11;330:788-796.

DOI: 10.1016/j.jconrel.2020.11.001

https://www.sciencedirect.com/science/article/pii/S0168365920306489?via%3Dihub

Reference (Okayama Univ. e-Bulletin): Professor MICHIUE's team

OU-MRU Vol.14: Simplified boron compound may treat brain tumours

Correspondence to

Associate professor MICHIUE Hiroyuki, M.D., Ph.D. Neutron Therapy Research Center, Okayama University, Shikata-cho 2-5-1, Okayama-city, Okayama 700-8558, Japan

E-mail: hmichiue@md.okayama-u.ac.jp

https://www.ntrc.okayama-u.ac.jp/en/index.html



Associate professor MICHIUE Hiroyuki

OKAYAMA

Further information

Okavama University

1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan

Public Relations Division

E-mail: www-adm@adm.okayama-u.ac.jp

Website: http://www.okayama-u.ac.jp/index e.html

Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/

We love OKAYAMA UNIVERSITY:

https://www.youtube.com/watch?v=7cXlttQIk3E

Okayama University Image Movie (2020):

https://www.youtube.com/watch?v=vQxeL0ztSLA

Okayama University supports the Sustainable Development Goals: https://sdgs.okayama- u.ac.jp/en/

Okayama University Medical Research Updates (OU-MRU)

The whole volume: OU-MRU (1-)

Vol.1: Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells

from blood samples for genetic testing

Vol.2: Ensuring a cool recovery from cardiac arrest





- Vol.3: Organ regeneration research leaps forward
- Vol.4: Cardiac mechanosensitive integrator
- Vol.5: Cell injections get to the heart of congenital defects
- Vol.6: Fourth key molecule identified in bone development
- Vol.7: Anticancer virus solution provides an alternative to surgery
- Vol.8: Light-responsive dye stimulates sight in genetically blind patients
- Vol.9: Diabetes drug helps towards immunity against cancer
- Vol.10: Enzyme-inhibitors treat drug-resistant epilepsy
- Vol.11: Compound-protein combination shows promise for arthritis treatment
- Vol.12: Molecular features of the circadian clock system in fruit flies
- Vol.13: Peptide directs artificial tissue growth
- Vol.14: Simplified boron compound may treat brain tumours
- Vol.15: Metamaterial absorbers for infrared inspection technologies
- Vol.16: Epigenetics research traces how crickets restore lost limbs
- Vol.17: Cell research shows pathway for suppressing hepatitis B virus
- Vol.18: Therapeutic protein targets liver disease
- Vol.19: Study links signalling protein to osteoarthritis
- Vol.20: Lack of enzyme promotes fatty liver disease in thin patients
- Vol.21: Combined gene transduction and light therapy targets gastric cancer
- Vol.22: Medical supportive device for hemodialysis catheter puncture
- Vol.23: <u>Development of low cost oral inactivated vaccines for dysentery</u>
- Vol.24: Sticky molecules to tackle obesity and diabetes
- Vol.25: Self-administered aroma foot massage may reduce symptoms of anxiety
- Vol.26: <u>Protein for preventing heart failure</u>
- Vol.27: Keeping cells in shape to fight sepsis
- Vol.28: Viral-based therapy for bone cancer
- Vol.29: Photoreactive compound allows protein synthesis control with light
- Vol.30: Cancer stem cells' role in tumor growth revealed
- Vol.31: Prevention of RNA virus replication
- Vol.32: Enzyme target for slowing bladder cancer invasion
- Vol.33: Attacking tumors from the inside
- Vol.34: Novel mouse model for studying pancreatic cancer
- Vol.35: Potential cause of Lafora disease revealed
- Vol.36: Overloading of protein localization triggers cellular defects
- Vol.37: Protein dosage compensation mechanism unravelled
- Vol.38: Bioengineered tooth restoration in a large mammal
- Vol.39: Successful test of retinal prosthesis implanted in rats
- Vol.40: Antibodies prolong seizure latency in epileptic mice
- Vol.41: Inorganic biomaterials for soft-tissue adhesion
- Vol.42: Potential drug for treating chronic pain with few side effects
- Vol.43: Potential origin of cancer-associated cells revealed
- Vol.44: Protection from plant extracts
- Vol.45: Link between biological-clock disturbance and brain dysfunction uncovered
- Vol.46: New method for suppressing lung cancer oncogene



- Vol.47: Candidate genes for eye misalignment identified
- Vol.48: Nanotechnology-based approach to cancer virotherapy
- Vol.49: Cell membrane as material for bone formation
- Vol.50: Iron removal as a potential cancer therapy
- Vol.51: Potential of 3D nanoenvironments for experimental cancer
- Vol.52: A protein found on the surface of cells plays an integral role in tumor growth and sustenance
- Vol.53: <u>Successful implantation and testing of retinal prosthesis in monkey eyes with</u> retinal degeneration
- Vol.54: Measuring ion concentration in solutions for clinical and environmental research
- Vol.55: <u>Diabetic kidney disease: new biomarkers improve the prediction of the renal prognosis</u>
- Vol.56: New device for assisting accurate hemodialysis catheter placement
- Vol.57: Possible link between excess chewing muscle activity and dental disease
- Vol.58: Insights into mechanisms governing the resistance to the anti-cancer medication cetuximab
- Vol.59: Role of commensal flora in periodontal immune response investigated
- Vol.60: Role of commensal microbiota in bone remodeling
- Vol.61: Mechanical stress affects normal bone development
- Vol.62: 3D tissue model offers insights into treating pancreatic cancer
- Vol.63: Promising biomarker for vascular disease relapse revealed
- Vol.64: Inflammation in the brain enhances the side-effects of hypnotic medication
- Vol.65: Game changer: How do bacteria play Tag?
- Vol.66: Is too much protein a bad thing?
- Vol.67: Technology to rapidly detect cancer markers for cancer diagnosis
- Vol.68: Improving the diagnosis of pancreatic cancer
- Vol.69: Early gastric cancer endoscopic diagnosis system using artificial intelligence
- Vol.70: Prosthetics for Retinal Stimulation
- Vol.71: The nervous system can contribute to breast cancer progression
- Vol.72: Synthetic compound provides fast screening for potential drugs
- Vol.73: <u>Primary intraocular lymphoma does not always spread to the central nervous system</u>
- Vol.74: Rising from the ashes—dead brain cells can be regenerated after traumatic injury
- Vol.75: More than just daily supplements herbal medicines can treat stomach disorders
- Vol.76: The molecular pathogenesis of muscular dystrophy-associated cardiomyopathy
- Vol.77: Green leafy vegetables contain a compound which can fight cancer cells
- Vol.78: Disrupting blood supply to tumors as a new strategy to treat oral cancer
- Vol.79: Novel blood-based markers to detect Alzheimer's disease
- Vol.80: A novel 3D cell culture model sheds light on the mechanisms driving fibrosis in pancreatic cancer
- Vol.81: Innovative method for determining carcinogenicity of chemicals using iPS cells
- Vol.82: Making memories the workings of a neuron revealed
- Vol.83: Skipping a beat a novel method to study heart attacks
- Vol.84: Friend to Foe—When Harmless Bacteria Turn Toxic



Vol.85: Promising imaging method for the early detection of dental caries

Vol.86: Plates and belts — a toolkit to prevent accidental falls during invasive vascular

procedures

Vol87: Therapeutic potential of stem cells for treating neurodegenerative disease



Okayama University Hospital (Okayama University Shikata Campus, Okayama City, Japan) http://www.okayama-u.ac.jp/eng/access maps/index.html



「Junko Fukutake Hall」 Kazuyo Sejima + Ryue Nishizawa / SANAA Okayama University (Shikata Campus, Okayama City) http://www.okayama-u.ac.jp/eng/access maps/index.html








Okayama University supports the Sustainable Development Goals


About Okayama University

Okayama University is one of the largest comprehensive universities in Japan with roots going back to the Medical Training Place sponsored by the Lord of Okayama and established in 1870. Now with 1,300 faculty and 13,000 students, the University offers courses in specialties ranging from medicine and pharmacy to humanities and physical sciences.

Okayama University is located in the heart of Japan approximately 3 hours west of Tokyo by Shinkansen.

Website: http://www.okayama-u.ac.jp/index_e.html





Okayama University Integrated Report

click



An integrated report is intended to explain how an organization creates value over time through an organic integration of the vision and the combination of financial information and other information. Through this report we hope to promote greater interest in Okayama University among readers everywhere. In order to help us make improvements in future editions, we encourage you to contact us with any comments and suggestions you may have.

President, Okayama University